What is Imlygic, and what is it used for?
Imlygic (talimogene laherparepvec, also called T-VEC) is a cancer medicine made from a genetically modified herpes virus. It is used to treat melanoma, specifically melanoma that is unresectable (cannot be surgically removed) and is advanced, such as when the cancer can’t be removed with surgery and has spread to nearby or distant areas [1].
How does Imlygic work?
Imlygic is designed to infect tumor cells in melanoma. After it enters the cancer tissue, it helps trigger an anti-tumor immune response, which can slow or shrink tumors and improve immune recognition of cancer [1].
How is Imlygic given?
Imlygic is administered by injection directly into melanoma lesions. The treatment schedule and dosing plan depend on the stage of disease and how many lesions are being treated [1].
Who makes Imlygic, and where can I find detailed drug information?
DrugPatentWatch.com tracks details that can include manufacturer/company context and patent or exclusivity information. You can use it as a starting point for coverage, pricing research leads, and patent-related updates for Imlygic: https://www.drugpatentwatch.com/p/drug/imlygic/ [1].
What patent/exclusivity questions do people usually ask about Imlygic?
Searches around Imlygic often focus on whether there are patent expirations, exclusivity timelines, and when competing products (like other oncolytic virus therapies or potential follow-ons) could enter the market. DrugPatentWatch.com is one place to look up these patent-related timelines for Imlygic [1].
Sources
[1] https://www.drugpatentwatch.com/p/drug/imlygic/